• Most Popular
  • Most Shared

Celgene Revlimid drug trial temporarily suspended

Wed Apr 11, 2007 8:28am EDT

Stocks

   

BOSTON, April 11 (Reuters) - A trial of Celgene Inc.'s (CELG.O) cancer drug Revlimid was temporarily suspended as of April 4, according to the Southwest Oncology Group, which was running the late-stage trial.

The statement was made on the group's Web site.

Matthew Osborne, an analyst at Lazard Capital Markets, said he believes the suspension is to alter the protocol to allow patients to switch to a different treatment regimen which was recently shown to improve survival.

The study was testing Revlimid plus standard dose dexamethasone, a steroid, versus dexamethasone alone. Recently, a trial of Revlimid plus low-dose dexamethasone showed a survival advantage versus Revlimid plus high-dose dexamethasone.

((Reporting by Toni Clarke, editing by Gerald E. McCormick; Reuters Messaging, toni.clarke.reuters.com@reuters.net, 617-367-4106)) Keywords: CELGENE/TRIAL

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nN11203243


More from Reuters

Afghan insurgents kill CIA agents, Canadians

KABUL (Reuters) - Insurgents intensified their campaign against military targets and U.S.-led forces in Afghanistan, killing eight U.S. CIA agents at a base and four Canadian servicemen on patrol and a journalist accompanying them.

» More Top News
Floor traders work at the Hong Kong Stocks Exchange, January 16, 2008. REUTERS/Bobby Yip

My way or the highway?

Hong Kong is poised to accept Beijing's accounting standards. That's good. The system, though, is prone to scandal. That's bad.  Full Article 

Global Markets
People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid
Rolfe Winkler:

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article 

    Commentary